Immuron Limited · ASX:IMC
Immuron — Emerging Growth Conference 2026
16 slides from Immuron's conference presentation, Oct 28, 2026
Slide 1: Immuron CEO presentation at Emerging Growth Conference
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference For personal use only Melbourne, Australia, October 28, 2026: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting at the Emerging Growth Conference on Wednes
Slide 2: Immuron Platform Technology
Immuron Platform Technology Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine
Slide 3: IBS market and references
them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS® to someone else. To learn more please check: www.proibs.eu. Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is For personal use on
Slide 4: Steven Lydeamore - CEO, October
NASDAQ: IMRN ASX: IMC rsonal use only 2 8 O C TO B E R 2 0 2 6 INVESTOR PRESENTATION S t e v e n Ly d e a m o r e - C E O 1
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r t a i n s t a t e m e nt s m a d e i n t h i s p re s e nt a t i o n a re fo r wa rd - l o o k i n g s t a t e m e nt s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c t a t i o n s , e s t i m a t e s a n d p ro j e c t i o n s . Wo rd s s u c h a s “a nt i
Slide 6: Immuron corporate and financial snapshot
Immuron Ltd is an Australian integrated biopharmaceutical company with global scale, focused on developing, and commercialising, oral products for the treatment of gut mediated diseases rsonal use only Technology Research & Financial Snapshot Development Global Corporate Platform Safe and potentiall
Slide 7: FY26 Financial Achievements
FY26 Financial Achievements rsonal use only United States Sales Global Sales Australian Sales Revenue Revenue Revenue $1.8m $7.7m $5.8m Up 7% Up 6% Up 10% Up 13% in $USD Gross Profit Margin Net Profit Cash 64.5% $(3.8)m $9.0m 0.9% $1.4m $6.2m2 decline1 improvement improvement 1. Gross Profit Margin
Slide 8: FY26 Clinical Achievements and Operational Highlights
FY26 Clinical Achievements and Operational Highlights rsonal use only New U.S. FDA approval Travelan® Department of IMM-529 n=851 trial Defense IND completed subaward Strategic reset Engaged Pullan New product launch aimed at Consulting to in Australia profitability and support partnering reduced ca
Slide 9: Continued strong sales growth
Continued strong sales growth Global Global Year to Date Jul - Sep Oct - Dec Jan - Mar Apr - Jun rsonal use only + Q1 FY27 AUD$2.2 million up 9% on prior year FY25 $ 1.5 $ 2.5 $ 1.3 $ 2.0 FY26 $ 2.0 $ 2.2 $ 1.5 $ 2.0 FY27 $ 2.2 Australia + Q1 FY27 AUD$1.8 million up 14% on prior year North America +
Slide 10: FY27 Outlook
FY27 Outlook rsonal use only Continued Travelan® Geographic sales Portfolio expansion sales growth expansion Continued Cash to fund Partnering update improvement in operations through for IMM-529 profitability and FY27 – FY28 reduced cash burn 7
Slide 11: Strategic reset provides clearer path to profitability
Immuron strategic reset provides clearer path to profitability Immuron has taken a strategic decision to partner clinical assets IMM-124E and IMM-529 for development and commercialization. rsonal use only • IMM-124E is eligible for an end of Phase 2 meeting with the U.S. FDA (indication: traveler’s
Slide 12: IMM-529: A First-in-Class Triple-Action CDI Biologic
IMM-529: A First-in-Class Triple-Action CDI Biologic The Opportunity: IMM-529 is an oral, non-systemic biological (hyperimmune bovine colostrum) for treatment and prevention of primary and recurrent Clostridioides difficile infection (CDI). Unlike antibiotics, IMM-529 eliminates rsonal use only the
Slide 13: IMM-529 Market Potential
IMM-529 Market Potential The Disease: C. difficile is the leading cause of healthcare-associated rsonal use only infection causing 400,000 cases and 30,000 deaths in the US annually Disease spectrum: • Mild-to-moderate: Watery persistent diarrhea, cramping • Severe/Pseudomembranous Colitis (PMC): Co
Slide 14: IMM-529 Deal Potential
IMM-529 Deal Potential Licensor / Asset Stage at Year Licensee / Acquirer Licensed Asset Financial terms (public) Status update (as of March 2026) Owner deal rsonal use only Asset sale signed Aug 2024 (public reporting FDA approved (Apr 2023) and commercialized by VOWST (SER-109) indicates deal stru
Slide 15: Institutional Investor Snapshot FY2026
IMMURON LIMITED (ASX:IMC / Nasdaq:IMRN) | Institutional Investor Snapshot FY2026 Revenue Market Cap. Cash Pipeline A$7.7m FY26 A$12.91m A$9.0m 2 Assets +6% YoY 26 October 2026 Partnering focus rsonal use only @30 June 26; 24-month runway Investment Catalysts (12-18 months) Risk / Reward Assessment T
Slide 16: Steven Lydeamore contact information
rsonal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172